{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:41:21Z","timestamp":1760384481839},"reference-count":56,"publisher":"Wiley","issue":"s4","license":[{"start":{"date-parts":[[2005,6,10]],"date-time":"2005-06-10T00:00:00Z","timestamp":1118361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bipolar Disorders"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:p>Atypical antipsychotics have been used to treat patients with schizophrenia for many years, but now there is increasing evidence of their utility in the treatment of bipolar disorder. In the past few years several atypical agents have received regulatory approval for use in bipolar mania. Through a review of randomized controlled trials for five commonly used atypical drugs, olanzapine, risperidone, quetiapine, ziprasidone and aripiprazole, this article evaluates their efficacy in the acute and maintenance phases of bipolar disorder. The evidence shows that atypical antipsychotics are effective in the treatment of manic symptoms, either alone or in combination with traditional mood stabilizers such as lithium and divalproex. Although emerging data indicate that atypical antipsychotics will be a promising addition to those therapies that are currently available for managing patients during the maintenance phase of bipolar illness, their potential in the long\u2010term management of bipolar disorder remains to be fully explored.<\/jats:p><jats:p>Atypical antipsychotics appear to have broadly similar efficacy against manic symptoms of bipolar disorder, but there are important differences in their tolerability profiles, which are likely to be of particular relevance during long\u2010term treatment. A brief assessment of tolerability issues surrounding the use of atypical agents in bipolar disorder and other aspects of treatment that have impact on the clinical effectiveness of the therapy are considered.<\/jats:p>","DOI":"10.1111\/j.1399-5618.2005.00212.x","type":"journal-article","created":{"date-parts":[[2005,6,10]],"date-time":"2005-06-10T09:24:49Z","timestamp":1118395489000},"page":"21-33","source":"Crossref","is-referenced-by-count":55,"title":["Atypical antipsychotics: newer options for mania and maintenance therapy"],"prefix":"10.1111","volume":"7","author":[{"given":"Eduard","family":"Vieta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M","family":"Goikolea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,6,10]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"1","article-title":"Practice guideline for the treatment of patients with bipolar disorder (revision)","volume":"159","author":"American Psychiatric Association Work Group on Bipolar Disorder","year":"2002","journal-title":"Am J Psychiatry"},{"key":"e_1_2_8_3_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania","volume":"156","author":"Tohen M","year":"1999","journal-title":"Am J Psychiatry"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.9.841"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n1210b"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/ebmh.5.3.89"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2003.07.005"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.1.62"},{"key":"e_1_2_8_9_2","volume-title":"Quetiapine for the Treatment of Rapid\u2010cycling Bipolar Depression","author":"Vieta E"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00334-8"},{"key":"e_1_2_8_11_2","first-page":"1420","volume-title":"Comparison of rapid\u2010cycling and non\u2010rapid\u2010cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data","author":"Vieta E","year":"2004"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.556"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.187.3.229"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.6.1057"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.7.1146"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.182.2.141"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2004.06.003"},{"key":"e_1_2_8_18_2","volume-title":"Quetiapine monotherapy for mania associated with bipolar disorder: analysis of two international, double\u2010blind, randomised, placebo\u2010controlled studies","author":"Vieta E","year":"2005"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2004.00115.x"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200210000-00011"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000144887.66319.2f"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.741"},{"key":"e_1_2_8_23_2","volume-title":"Ziprasidone in Adjunctive Treatment of Acute Bipolar Mania: Randomized, Double\u2010blind, Placebo\u2010controlled Trial","author":"Weisler R"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418060-00007"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.9.1651"},{"key":"e_1_2_8_26_2","volume-title":"Efficacy of Aripiprazole in Acute Mania: A New Acute, Placebo\u2010controlled Study","author":"Yocca F","year":"2003"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.187.3.235"},{"key":"e_1_2_8_28_2","volume-title":"A Three\u2010week Comparison of Olanzapine Versus Risperidone in the Treatment of Bipolar Mania: Improvement in Manic and Depressive Symptoms and Treatment Adherence","author":"Baker RW"},{"key":"e_1_2_8_29_2","volume-title":"Risperidone Versus Olanzapine as Adjunctive Therapy in the Treatment of Patients with Bipolar Disorder who are Receiving a Primary Thymoleptic Agent","author":"Petrie WM"},{"key":"e_1_2_8_30_2","first-page":"73","article-title":"Lithium: a review of its pharmacokinetics, health effects, and toxicology","volume":"13","author":"Marcus WL","year":"1994","journal-title":"J Environ Pathol Toxicol Oncol"},{"key":"e_1_2_8_31_2","volume-title":"Olanzapine Versus Placebo for Relapse Prevention in Bipolar Disorder","author":"Tohen MF"},{"key":"e_1_2_8_32_2","volume-title":"Olanzapine versus lithium in relapse\/recurrence prevention in bipolar disorder: a randomized double\u2010blind controlled 12\u2010month clinical trial","author":"Tohen M","year":"2005"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1011"},{"key":"e_1_2_8_34_2","volume-title":"Combination Quetiapine Therapy in the Long\u2010term Treatment of Patients with Refractory Bipolar I Disorders","author":"Carta MG"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2002.01204.x"},{"key":"e_1_2_8_36_2","unstructured":"MarcusR CarsonW McQuadeR SanchezR IwamotoT StockE.Long\u2010term efficacy of aripiprazole in the maintenance treatment of bipolar disorder. 42nd Annual Meeting of the American College of Neuropsychopharmacology San Juan Puerto Rico 7\u201312 December 2003."},{"issue":"6","key":"e_1_2_8_37_2","first-page":"18","article-title":"Response, remission, and recovery in bipolar disorders: what are the realistic treatment goals?","volume":"64","author":"Sachs GS","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"e_1_2_8_38_2","first-page":"29","article-title":"Extrapyramidal side effects and tolerability of risperidone: a review","volume":"55","author":"Owens DGC","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_8_39_2","author":"Eli Lilly and Company","journal-title":"Zyprexa\u00ae Olanzapine Tablets\/US Prescribing Information"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(98)00090-6"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(03)00050-1"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00190-X"},{"key":"e_1_2_8_43_2","author":"Bristol\u2010Myers Squibb","journal-title":"Aripiprazole Prescribing Information"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0907"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.11.1686"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0802"},{"key":"e_1_2_8_47_2","volume-title":"Persistence with Initially Prescribed Antipsychotic Medication and Economic Outcomes in the Treatment of Bipolar Disorder","author":"White RE"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2004.00411.x"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.12.1218"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199911000-00003"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.6.1011"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0310"},{"key":"e_1_2_8_53_2","first-page":"176","article-title":"Risperidone compared with both lithium and haloperidol in mania: a double\u2010blind randomized controlled trial","volume":"21","author":"Segal J","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(98)00023-5"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.3.12.1773"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4530(02)00110-5"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.3109\/10401230209147398"}],"container-title":["Bipolar Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-5618.2005.00212.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-5618.2005.00212.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T03:02:13Z","timestamp":1695783733000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-5618.2005.00212.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,10]]},"references-count":56,"journal-issue":{"issue":"s4","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1111\/j.1399-5618.2005.00212.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-5618.2005.00212.x","archive":["Portico"],"relation":{},"ISSN":["1398-5647","1399-5618"],"issn-type":[{"value":"1398-5647","type":"print"},{"value":"1399-5618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,10]]}}}